If you live in Czechia and have searched anything about weight loss lately, one brand name has almost certainly come up – and it is the one most surrounded by misunderstanding. The medicine behind it is not a weight-loss product, and Czech prescribing rules are stricter than in most EU countries. Here is what it is approved for, what the e-prescription system actually allows, and what that means if you are dealing with obesity here.

What Ozempic is approved for in the EU

Ozempic contains semaglutide, a GLP-1 receptor agonist, given as a once-weekly injection from a pre-filled pen. The European Medicines Agency authorised it for a single purpose: the treatment of adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise, either alone when metformin is unsuitable or added to other diabetes medicines (EMA: Ozempic).

Weight management is not among its authorised indications. In the diabetes trials assessed by the regulator, treatment with Ozempic was associated with a beneficial fall in body weight (EMA: Ozempic), which is how the brand became attached to weight loss in public conversation. But a weight effect observed during treatment of a different condition is not an approved obesity treatment. In Czechia that distinction is not only legal and clinical, it is technical.

Czech e-prescription rules: a diabetes diagnosis is required

Czechia hard-coded limits into the national eRecept system. Since 7 April 2023, an Ozempic prescription is rejected unless it meets all of these conditions (ePreskripce.gov.cz, in Czech):

the prescription carries a diagnosis of diabetes mellitus (type 1 or type 2);
the prescriber holds a specialisation in internal medicine, diabetology or endocrinology;
the quantity dispensed does not exceed 12 mg of active substance per 12 weeks;
the payment type "patient pays" cannot be selected – the prescription has to run through health insurance.

A prescription failing any of these is flagged as a hard error and does not go through. Stated plainly: in Czechia there is no lawful route to a self-pay prescription of this product for weight loss, at any price, from any prescriber, in a clinic or online.

Why demand for weight loss caused shortages

The restriction did not appear out of nowhere. In spring 2023 the manufacturer failed to deliver planned volumes to the Czech Republic, citing production capacity and sharply increased EU-wide demand. eRecept data showed a rising trend of prescriptions issued in self-pay mode, and the Ministry of Health instructed SÚKL to limit prescribing to the three specialisations above, so that constrained supply reached the patients the medicine is approved and reimbursed for (Ministry of Health, April 2023, in Czech). Further interruptions to some strengths followed in July 2024 (manufacturer letter published by SÚKL, in Czech, PDF). Supply across the GLP-1 class has fluctuated since, so availability is worth checking – see GLP-1 availability in Czech pharmacies.

Counterfeits: why "no prescription" offers are a red flag

SÚKL has warned about a growing number of suspected counterfeit Ozempic pens circulating in the EU, affecting the 0.25 mg, 0.5 mg and 1 mg presentations. The regulator reports no information about counterfeit packs in the Czech legal distribution chain, and stresses that the medicine can be obtained legally only by dispensing at a pharmacy (SÚKL warning, in Czech). A counterfeit seized in Austria contained insulin instead of semaglutide; people who injected it had seizures and severe hypoglycaemia (ČT24, in Czech).

The rule of thumb is simple. In Czechia the only lawful path to any prescription medicine runs through a prescription and dispensing at a pharmacy counter. Mail-order supply of prescription medicines is illegal here: under § 85(1) of Act No. 378/2007 Coll. on Pharmaceuticals, only registered medicines whose dispensing is not tied to a prescription may be sent by post (SÚKL questions and answers, in Czech). So any site promising to post one to your address in Prague or elsewhere is outside the law, and what arrives is unverifiable. The warning signs are in illegal online pharmacies in Czechia.

How treatment for obesity is actually accessed here

If your concern is obesity rather than diabetes, the first step is not hunting for a particular product but a proper medical assessment. A doctor reviews your BMI, medical history, other medicines you take and your goals, then decides whether pharmacological treatment is appropriate at all. That assessment is not a formality: the doctor may conclude it is not suitable and decline it. Our BMI calculator gives you a starting point, but a calculator decides nothing.

Not having a registered GP is not an obstacle. Of the 554,000 people in Czechia without a registered GP, 65% are foreign nationals – roughly 360,000 people (expats.cz), and this care pathway does not require one, as we explain in obesity treatment in Czechia without a GP. At GoOn you complete an online questionnaire, then speak to a licensed Czech doctor by video in English, with no surcharge for the language. If the doctor concludes treatment is appropriate, they issue a standard Czech eRecept, which you collect at any pharmacy in the country; nothing is posted to you. Check with a doctor online whether treatment is suitable for you. You pay only for the consultations, and the medicine is paid separately at the pharmacy – see what weight-loss treatment costs in Czechia.

Which medicines do carry an obesity indication

At class level, the EU has authorised products specifically for weight management in adults meeting defined BMI criteria: semaglutide at a higher weekly dose (EMA: Wegovy) and tirzepatide (EMA: Mounjaro). They differ in dosing, evidence base and safety profile, and no product is right in the abstract.

This is where the dose distinction becomes concrete: the weight-management evidence for semaglutide comes from a higher weekly dose than the diabetes product provides. In the STEP 1 trial, participants with overweight or obesity and without type 2 diabetes taking semaglutide 2.4 mg lost on average 14.9% of body weight over 68 weeks, against 2.4% on placebo, with both groups also changing diet and physical activity (NEJM). A trial average is not a personal forecast; individual response varies widely, and some people respond weakly or stop early. A balanced comparison of the class, limitations included, is in GLP-1 medicines compared.

Side effects and contraindications

The most common adverse effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhoea, constipation and abdominal pain, most pronounced at the start and when the dose is increased. Less common but serious events include pancreatitis and gallbladder problems, and the medicine is not intended for use in pregnancy or breastfeeding (EMA: Ozempic). Taken alongside insulin or sulfonylureas, it raises the risk of hypoglycaemia. The full list of contraindications, warnings and interactions is in the summary of product characteristics, published in English as part of the EPAR product information for Ozempic. Whether treatment is suitable is always a doctor's decision, weighing benefits and risks for the individual patient.

Practical points for foreigners living in Czechia

Two details catch people out. A Czech eRecept can be issued even without a Czech insurance number: a medicine that is not reimbursed can be prescribed without an insurance number and insurer code (ePreskripce FAQ on prescribing without an insurance number, in Czech). Foreigners without permanent or long-term residence are also never matched against the Register of Inhabitants, so the record stays unidentified – which blocks neither issuing nor dispensing, and only means the prescription will not show in your shared medication record (ePreskripce, in Czech). So bring the eRecept identifier itself to the counter, whether as a printed slip or sent to you by SMS or e-mail (ePreskripce, in Czech). And cross-border acceptance of foreign e-prescriptions here is only partial, as just a subset of pharmacies participates (ePreskripce, in Czech) – which is why a natively issued Czech prescription is more reliable for residents. See our guide to the Czech eRecept and, if you arrive mid-treatment, continuing GLP-1 treatment after moving to Czechia.

Frequently asked questions

Is Ozempic prescribed for weight loss in Prague?

No. The eRecept system requires a diabetes diagnosis on the prescription and blocks the self-pay payment type, so a weight-loss prescription for this product cannot lawfully be issued anywhere in the country (ePreskripce, in Czech). Obesity is treated with products carrying a weight-management indication, and only if a doctor judges treatment appropriate.

Is Ozempic available over the counter in the Czech Republic?

No. It is prescription-only and can be dispensed legally only at a pharmacy. Offers to sell it without a prescription, or to post it to your address, are illegal in Czechia and are associated with counterfeits, which have contained the wrong active substance entirely.

Does Czech public insurance cover weight-loss medication for foreigners?

Public insurance covers what it covers for everyone equally, and as of August 2026 medicines used for weight management are not publicly reimbursed in Czechia for obesity. The Ministry of Health says targeted reimbursement for defined patient groups is at an initial discussion stage, with blanket coverage of obesity treatment called unrealistic on cost grounds (finance.cz, May 2026, in Czech). That means self-payment for Czechs and foreigners alike, with no separate foreigner price. Details are in Czech health insurance and weight-loss medication.

Do I need a Czech GP before I can be assessed?

No. Of the 554,000 people in Czechia without a registered GP, 65% are foreign nationals – roughly 360,000 people (expats.cz), and an assessment for obesity treatment needs no referral from one. A licensed Czech doctor takes your history, decides whether treatment is appropriate, and may also decide that it is not.